The intestinal microbiota and susceptibility to infection in immunocompromised patients

Current Opinion in Infectious Diseases

Volumn 26, Issue 4, 2013, Pages 332-337

  Taur, Ying ^a,b   Pamer, Eric G ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

gastrointestinal tract; immunosuppression; microbiome; microbiota; neutropenia

Indexed keywords

PENICILLIN DERIVATIVE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC THERAPY; BACTERIAL FLORA; BACTERIAL TRANSLOCATION; BLOODSTREAM INFECTION; CANCER CHEMOTHERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMENSAL; ENTEROCOCCUS; ESCHERICHIA COLI; FECES MICROFLORA; GASTROINTESTINAL TRACT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION SENSITIVITY; INFECTIOUS COMPLICATION; INTESTINE FLORA; KLEBSIELLA PNEUMONIAE; MICROBIAL COMMUNITY; NEUTROPENIA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALMONELLA; SHIGELLA; VANCOMYCIN RESISTANT ENTEROCOCCUS;

BACTERIAL INFECTIONS; GASTROINTESTINAL TRACT; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOCOMPROMISED HOST;

EID: 84879848972     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283630dd3     Document Type: Review

References (64)

1. Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients. Cancer 2006; 107:1743-1751.
2. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012; CD004386.
3. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353:977-987. (Pubitemid 41262332)
4. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56-e93.
5. Jaffe D, Jakubowski A, Sepkowitz K, et al. Prevention of peritransplantation viridans streptococcal bacteremia with early vancomycin administration: a single-center observational cohort study. Clin Infect Dis 2004; 39:1625-1632. (Pubitemid 39578536)
6. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29:490-494. (Pubitemid 29439940)
7. Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 2005; 40:S246-S252. (Pubitemid 40411206)
8. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330:1240-1241. (Pubitemid 24122001)
9. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 2012; 336:1268-1273.
10. Sekirov I, Finlay BB. The role of the intestinal microbiota in enteric infection. J Physiol 2009; 587:4159-4167.
11. Van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog 2010; 6:e1000879.
12. Bohnhoff M, Drake BL, Miller CP. Effect of streptomycin on susceptibility of intestinal tract to experimental Salmonella infection. Proc Soc Exp Biol Med 1954; 132-137.
13. Miller C,Bohnhoff M, Drake B. The effect of antibiotic therapy on susceptibility to an experimental enteric infection. Trans Assoc Am Physicians 1954; 67:156.
14. Freter R. In vivo and in vitro antagonism of intestinal bacteria against Shigella flexneri: II. The inhibitory mechanism. J Infect Dis 1962; 110:38-46.
15. Vollaard E, Clasener H. Colonization resistance. Antimicrob Agents Chemother 1994; 38:409.
16. Van der Waaij D, Berghuis-de Vries J, Lekkerkerk-Van der Wees J. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J Hygiene 1971; 69:405-411.
17. Vollaard E, Clasener H, Janssen A, Wynne H. Influence of cefotaxime on microbial colonization resistance in healthy volunteers. J Antimicrob Chemother 1990; 26:117-123. (Pubitemid 20263704)
18. Vollaard E, Clasener H, van Griethuysen A, et al. Influence of amoxycillin, erythromycin and roxithromycin on colonization resistance and on appearance of secondary colonization in healthy volunteers. J Antimicrob Chemother 1987; 20:131.
19. Vollaard E, Clasener H, Janssen A, Wynne H. Influence of amoxycillin on microbial colonization resistance in healthy volunteers. J Antimicrob Chemother 1990; 25:861-871. (Pubitemid 20183048)
20. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9:313-323.
21. Huttenhower C, Gevers D, Knight R, et al. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486:207-214.
22. Snitkin ES, Zelazny AM, Thomas PJ, et al. Tracking a hospital outbreak of carbapenem-resistant klebsiella pneumoniae with whole-genome sequencing. Sci Translation Med 2012; 4:148ra116-148ra116.
23. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353: 988-998. (Pubitemid 41262333)
24. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2005; CD004386.
25. Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 55:905-914.
26. Lupp C, Robertson ML, Wickham ME, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007; 2:119-129. (Pubitemid 47209521)
27. Stecher B, Robbiani R, Walker AW, et al. Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLoS Biol 2007; 5:e244.
28. Sekirov I, Gill N, Jogova M, et al. Salmonella SPI-1-mediated neutrophil recruitment during enteric colitis is associated with reduction and alteration in intestinal microbiota. Gut Microbes 2010; 1:30.
29. Winter SE, WinterMG, Xavier MN, et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 2013; 339:708-711.
30. Ubeda C, Taur Y, Jenq RR, et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest 2010; 120:4332.
31. Sekirov I, Tam NM, Jogova M, et al. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infect Immun 2008; 76:4726-4736.
32. Ayres JS, Trinidad NJ, Vance RE. Lethal inflammasome activation by a multidrug- resistant pathobiont upon antibiotic disruption of the microbiota. Nat Med 2012; 18:799-806.
33. Endt K, Stecher B, Chaffron S, et al. The microbiota mediates pathogen clearance from the gut lumen after nontyphoidal Salmonella diarrhea. PLoS Pathog 2010; 6:e1001097.
34. Ferreira RB, Gill N, Willing BP, et al. The intestinal microbiota plays a role in Salmonella-induced colitis independent of pathogen colonization. PLoS One 2011; 6:e20338.
35. Bochud P-Y, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994; 97:256-264. (Pubitemid 24284365)
36. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002; 34:1524-1529. (Pubitemid 34553713)
37. Richard P, Felice M, Daeschler T, et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet 1995; 345:1607-1609.
38. Bochud P-Y, Eggiman P, Calandra T, et al. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18:25-31. (Pubitemid 24025915)
39. Cunha BA. Vancomycin revisited: a reappraisal of clinical use. Crit Care Clin 2008; 24:393-420. (Pubitemid 351400623)
40. Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer 2011; 19:231-237.
41. Worth LJ, Thursky KA, Seymour JF, Slavin MA. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol 2007; 79:226-233. (Pubitemid 47241068)
42. Tsiatis A, Manes B, Calder C, et al. Incidence and clinical complications of vancomycin-resistant enterococcus in pediatric stem cell transplant patients. Bone marrow Transplant 2004; 33:937-941. (Pubitemid 38660127)
43. Kamboj M, Chung D, Seo SK, et al. The changing epidemiology of vancomycin- resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant 2010; 16:1576-1581.
44. Weinstock DM, Conlon M, Iovino C, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2007; 13:615-621. (Pubitemid 46585935)
45. Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20:1126-1133.
46. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000; 343:1925-1932. (Pubitemid 32064786)
47. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis 1999; 180:384-390. (Pubitemid 30256319)
48. Roghmann M-C, McCarter RJ, Brewrink J, et al. Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-colonized patients with acute leukemia. Clin Infect Dis 1997; 25:1056-1059. (Pubitemid 27513185)
49. Ubeda C, Bucci V, Caballero S, et al. Intestinal microbiota containing barnesiella species cures vancomycin-resistant enterococcus faecium colonization. Infect Immun 2013; 81:965-973.
50. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7:526-536.
51. Hasegawa M, Kamada N, Jiao Y, et al. Protective role of commensals against Clostridium difficile infection via an IL-1b-mediated positive-feedback loop. J Immunol 2012; 189:3085-3091.
52. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent clostridium difficile-associated diarrhea. J Infect Dis 2008; 197:435-438. (Pubitemid 351263426)
53. Reeves AE, Koenigsknecht MJ, Bergin IL, Young VB. Suppression of Clostridium difficile in the gastrointestinal tract of germ-free mice inoculated with a murine lachnospiraceae isolate. Infect Immunity 2012; 80:3786-3794.
54. Jarchum I, Liu M, Shi C, et al. Critical role for MyD88-mediated neutrophil recruitment during clostridium difficile colitis. Infect Immunity 2012; 80: 2989-2996.
55. Jarchum I, Liu M, Lipuma L, Pamer EG. Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect Immunity 2011; 79:1498-1503.
56. Lawley TD, Clare S, Walker AW, et al. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immunity 2009; 77:3661-3669.
57. Hasegawa M, Yamazaki T, Kamada N, et al. Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen. J Immunol 2011; 186:4872-4880.
58. Khoruts A, Dicksved J, Jansson JK, SadowskyMJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010; 44:354.
59. Bakken JS, Johnson S, Gerding D. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009; 15:285-289.
60. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9:1044-1049.
61. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53:994-1002.
62. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-415.
63. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989; 1:1156.
64. Lawley TD, Clare S, Walker AW, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012; 8:e1002995.